TY - JOUR
T1 - Therapeutic potential for novel ultra long-acting beta(2)-agonists in the management of COPD: biological and pharmacological aspects
AU - MALERBA, Mario
AU - Radaeli, A
AU - Morjaria, J. B.
N1 - Funding Information:
JB Morjaria has received honoraria for speaking and financial support to attend meetings from Chiesi, Pfizer, MSD, Boehringer Ingelheim and GSK. Mario Malerba has received honoraria for speaking and financial support to attend meetings from Chiesi, Pfizer, Boehringer Ingelheim, Astra Zeneca and Novartis.
PY - 2012
Y1 - 2012
N2 - Chronic obstructive pulmonary disease (COPD) is characterised by progressive airflow limitation. In moderate-to-severe COPD, long-acting bronchodilators are the basis of therapy. Inhaled long-acting β 2-agonists (LABAs) are used for the treatment of COPD. LABAs have been in use since the 1990s enabling persistent bronchodilation for 12 hours; however, sustained bronchodilation is desirable. Compared with twice-daily LABAs, new LABAs with ultra-long duration (ultra-LABAs) could provide improvements in efficacy and compliance with fast onset of action, 24-hour bronchodilation and a good safety profile. Several novel ultra-LABAs showing once-daily delivery profiles are in development. In this article, we discuss these novel agents' properties and clinical trials of their efficacy and safety, including the only licensed ultra-LABA, indacaterol.
AB - Chronic obstructive pulmonary disease (COPD) is characterised by progressive airflow limitation. In moderate-to-severe COPD, long-acting bronchodilators are the basis of therapy. Inhaled long-acting β 2-agonists (LABAs) are used for the treatment of COPD. LABAs have been in use since the 1990s enabling persistent bronchodilation for 12 hours; however, sustained bronchodilation is desirable. Compared with twice-daily LABAs, new LABAs with ultra-long duration (ultra-LABAs) could provide improvements in efficacy and compliance with fast onset of action, 24-hour bronchodilation and a good safety profile. Several novel ultra-LABAs showing once-daily delivery profiles are in development. In this article, we discuss these novel agents' properties and clinical trials of their efficacy and safety, including the only licensed ultra-LABA, indacaterol.
UR - https://iris.uniupo.it/handle/11579/88597
U2 - 10.1016/j.drudis.2011.11.002
DO - 10.1016/j.drudis.2011.11.002
M3 - Article
SN - 1359-6446
VL - 17
SP - 496
EP - 504
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 9-10
ER -